Condition: Neuroblastoma · Diffuse Intrinsic Pontine Glioma · Sponsor: University of Florida
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).
This description comes directly from the study's public registry record.
BCC Enroll · 717-531-0003 · BCCEnroll@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Levine Children's Hospital | Charlotte, North Carolina, United States | Active Not Recruiting |
| Penn State Milton S. Hershey Medical Center and Children's Hospital | Hershey, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04837547